Risk Assessment of Human Carcinogenicity of Acrylamide in Food: Way to Reduce the Predicted Mitogenic Side Effects Through Mitigation Strategy

2021 ◽  
pp. 855-868
Author(s):  
Heba K. Nabih
Keyword(s):  
Risk Assessment ◽  
Side Effects ◽  
Mitigation Strategy

Arc flash: a risk assessment and mitigation strategy

2011 ◽  
Vol 51 (2) ◽  
pp. 737
Author(s):  
Danny Norton ◽  
Dale Wright
Keyword(s):  
Risk Assessment ◽  
Oil And Gas ◽  
Capital Expenditure ◽  
Risk Mitigation ◽  
Cumulative Effect ◽  
Mitigation Strategy ◽  
Assessment Process ◽  
Mitigation Measures ◽  
Safe Work ◽  
Arc Flash

Oil and gas facility managers are well aware that attention to detail saves lives and supports business continuity and reputation. Those tasked with stewardship of electrical assets will be aware of the need to protect their employees from the hazard of electrical arc flash and that it should be at the forefront of safety thinking. Complacency and lack of duty of care with this real and possibly un-quantified hazard can lead to fatalities. The primary solution to arc flash consequences in older installations has been the implementation of safe work procedures and personal protective equipment. While still valid, these solutions are the least effective options in the hierarchy of controls. SKM have developed a practical risk mitigation strategy that considers the hazards of prospective arc flash energy together with the cumulative effect of switchboard age, design, capability and condition. The strategy also considers the range of potential mitigation controls available through the mechanism of substitution and engineering design that focuses on reducing: The likelihood of an arc flash incident occurring; The likelihood of personnel exposure; and, The energy released should an incident occur. A structured arc flash risk assessment process can provide the asset owner the opportunity to rank individual switchboards for likelihood, consequence and risk, and thus provide direction for engineered remediation and capital expenditure. SKM proposes the way in which arc flash risk can be assessed, how appropriate layered mitigation measures might be selected, and how an asset owner may approach the issue of arc flash hazard mitigation to economically and reliably protect its employees.

scholarly journals Neonicotinoids in bees: a review on concentrations, side-effects and risk assessment

Ecotoxicology ◽  
2012 ◽  
Vol 21 (4) ◽  
pp. 973-992 ◽  
Author(s):  
Tjeerd Blacquière ◽  
Guy Smagghe ◽  
Cornelis A. M. van Gestel ◽  
Veerle Mommaerts
Keyword(s):  
Risk Assessment ◽  
Side Effects

scholarly journals Evidence for side effects of cannabidiol (CBD) products and their non-conformity on the European food market – response to the European Industrial Hemp Association

F1000Research ◽  
2020 ◽  
Vol 9 ◽  
pp. 1051
Author(s):  
Dirk W. Lachenmeier ◽  
Stephan G. Walch
Keyword(s):  
Risk Assessment ◽  
Side Effects ◽  
The European Union ◽  
Ample Evidence ◽  
Food Ingredients ◽  
Toxicological Assessment ◽  
Federal Institute ◽  
Legal Situation ◽  
Food Market ◽  
Industrial Hemp

An interesting and valuable discussion has arisen from our recent article (Lachenmeier et al., 2020) and we are pleased to have the opportunity to expand on the various points we made. Equally important, we wish to correct several important misunderstandings that were made by Kruse and Beitzke (2020) on behalf of the European Industrial Hemp Association (EIHA) that possibly contributed to their concerns about the validity of our data, toxicological assessment and conclusions regarding regulatory status of cannabidiol (CBD) products. First and foremost, our study did only assess the risk of psychotropic Δ9-tetrahydrocannabinol (THC) without inclusion of non-psychotropic Δ9-tetrahydrocannabinolic acid (THCA). Secondly, as this article will discuss in more detail, there is ample evidence for side effects of CBD products, not only in paediatric patients, but also in adult users of over-the-counter CBD products (including inadvertent “high” effects). Thirdly, the exposure and risk assessment was conducted using up-to-date guidelines according to the European Food Safety Authority (EFSA) and the German Federal Institute for Risk Assessment (BfR). And finally, the current legal situation in the European Union, without approval of any hemp extract-containing product according to the Novel Food regulation, actually allows blanket statements that all such products are illegal on the market, and this indeed would imply a general ban on the use and marketing of such products as food or food ingredients until such an approval has been granted. We hope that this reassures the F1000Research readership regarding the validity of our results and conclusions. We are pleased, though, that the EIHA has acknowledged the fact that there are non-compliant CBD products available, but according to our data these are a substantial fraction of the market.

Violence and Psychosis; Treating the Untreatable (Novel Pharmacological Approaches)

2009 ◽  
Vol 24 (S1) ◽  
pp. 1-1
Author(s):  
M. Launer
Keyword(s):  
Risk Assessment ◽  
Side Effects ◽  
Effective Treatment ◽  
High Dose ◽  
Therapy Process ◽  
Stable Patient ◽  
Treatment Resistant ◽  
Early Use ◽  
Future Risk ◽  
Depot Preparations

Often the final pathway for psychosis is the forensic services. in many other cases the only options are prison or no care at all. Despite much research into the psychopharmacological approach many patients are either unresponsive or unable or unwilling to take medication. Many clinicians would support the early use of clozapine for these patients but despite the availability of clozapine in Europe for nearly 20 years the numbers who are treatment resistant are still highly significant. This affects patients, carers and indeed potential victims and staff who are increasingly vulnerable. the eclipse of the typical anti-psychotics and the fear of extra-pyramidal side effects has led to many patients being prescribed oral atypical agents which they do not actually take. the result of, in many cases years, of untreated or part treated psychosis is severe cognitive damage. This then contributes to difficulty in managing the patient and lack of engagement in the therapy process. the emergence of new depot preparations may be the answer but the degree of D2 blockade may still not be sufficient and the addition of 5HT blockade may be also useful. in the forensic settings there is much made of risk assessment but the most efficient predictor of future risk is a stable patient on an effective treatment regime. Several options are described including double depot, high dose olanzapine and clozapine enhancement.

Surgery, Chemotherapy, and Radiotherapy for Gynaecological Cancer

2021 ◽  
pp. 356-364
Author(s):  
Konstantinos Pantazis ◽  
Ioannis Andronikidis ◽  
Lazaros Nikiforidis ◽  
Anne Floquet ◽  
Konstantinos Dinas
Keyword(s):  
Risk Assessment ◽  
Decision Making ◽  
Side Effects ◽  
High Risk ◽  
Complication Rates ◽  
Benefit Ratio ◽  
Oncology Treatment ◽  
Complications Of Surgery ◽  
All Treatment

Gynaecological oncology treatment yields no fewer complications and side effects than those met in any other oncology field. Patients and clinicians are highly alerted by the ominous diagnosis and sometimes seek for high risk, experimental, or even unproven therapies and are consequently prepared to accept high complication rates that would otherwise be unacceptable. Still, risk reduction remains a high priority. This is achieved by appropriate risk assessment, risk-to-benefit ratio balancing, treatment individualisation, close follow up through all treatment stages, and prompt patient informing and participation in decision making. The chapter aims to summarize the main complications of surgery, chemotherapy, and radiotherapy as well as the main ways to overcome them.

Sign in / Sign up

Export Citation Format

Share Document